A recent report has suggested therapeutically targeting phosphoinositide 3 kinase (PI3K)/mTOR signaling in conjunction with suppression of JAK2/STAT5 in certain triple-negative breast cancers[82]. The gene discussed is MTOR; the disease is triple-negative breast carcinoma.